A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy
Sponsor study identifier
interventional
60
1 country
24
Study Start
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2006
Actual (reported)Study Completion
December 2006
Actual (reported)The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of CA 125 levels.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
June 3, 2004
Actual (reported)June 7, 2004
Actual (reported)February 2006
Actual (reported)December 2006
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Alabama, Birmingham
Birmingham, Alabama, 35233, United States
Desert Oasis Cancer Center
Casa Grande, Arizona, 85222, United States
California Oncology of the Central Valley
Fresno, California, 93710, United States
USC Keck School of Medicine Women's and Childrens Hospital
Los Angeles, California, 90033, United States
University of California Irvine Medical Center
Orange, California, 92668, United States
UC Davis Health System
Sacramento, California, 95817, United States
Scripps Cancer Center
First Submitted
June 3, 2004
First Posted
June 7, 2004
Study Start
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
February 2006
Actual (reported)A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Contact the study team to confirm eligibility.
San Diego, California, 92121, United States
University of Colorado Cancer Center
Aurora, Colorado, 80010, United States
Florida Hospital Cancer Institute
Orlando, Florida, 32804, United States
Medical College of Georgia Dept. of OB/GYN
Saint Agusta, Georgia, 30912, United States
Tripler Army Medical Center
Honolulu, Hawaii, 96859, United States
Gynecologic Oncology
Hinsdale, Illinois, 60521, United States
St. Vincent Gyn-Onc
Indianapolis, Indiana, 46260, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46617, United States
University of Louisville JG Brown Cancer Center
Louisville, Kentucky, 40202, United States
Hematology & Oncology Specialists
New Orleans, Louisiana, 70115, United States
Barnes Jewish Hospital
St Louis, Missouri, 63110, United States
Gabrail Cancer Center
Canton, Ohio, 44718, United States
OSU College of Medicine
Columbus, Ohio, 43210, United States
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, 73190, United States
Gynecologic-Oncology Research and Development, LLC
Greenville, South Carolina, 29601, United States
Chattanooga GYN Oncology
Chattanooga, Tennessee, 37403, United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234, United States
Carilion Gynecologic Oncology Associates
Roanoke, Virginia, 24014, United States
Study Completion
December 2006
Actual (reported)Last Updated
January 24, 2013
Record last verified: 2013-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: